Masimo Announces FDA Clearance and Full Market Release of the New Pronto-7 for Noninvasive Total Hemoglobin Spot-Check Measurement

by Eddie Staley, Benzinga Editor
January 9, 2012 12:24 PM | 12 seconds read |
Masimo MASI today announced FDA 510(k) clearance and full market commercial launch of the Masimo Pronto-7®—a palm-sized handheld device designed for quick and easy noninvasive spot-checking of total hemoglobin (SpHb®), SpO2, pulse rate, and perfusion index.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDAHealth CareHealth Care Equipment
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!